Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences

Epidemiologia e Psichiatria Sociale

Volumn 18, Issue 3, 2009, Pages 240-247

  Santone, Giovanni ^a   Ricchi, Gianmatteo ^a   Rocchetti, David ^a   Toeani, Stefania ^a   Bellantuono, Cesario ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Antidepressant drugs; Pregnancy; Spontaneous abortion

Indexed keywords

ANTIDEPRESSANT AGENT;

CHEMICALLY INDUCED DISORDER; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PREGNANCY; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

EID: 75549085811     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x0000052x     Document Type: Article

References (52)

1. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S. & Friedman J.M. for the National Birth Defects Prevention Studies. (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine 356, 2684-2692.
2. American. College of Obstetricians and Gynecologists. (2008). ACOG Practice Bulletin Number 92, April 2008. Obstetrics & Gynecology 4, 1001-1020.
3. Beck C.T., Records S. & Rice M. (2006). Further development of the Post-partum Depression Predictors Inventory-Revised. Journal of Obstetric, Gynecologic & Neonatal Nursing 35, 735-745.
4. Bellantuono C., Migliarese G. & Gentile S. (2007). Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Human Psychopharmacology 22, 121-128. (Pubitemid 46730580)
5. Bennett H.A., Einarson A., Taddio A., Koren G. & Einarson T. (2004). Prevalence of depression during pregnancy: systematic review. Obstetrics & Gynecology 103, 698-709. (Pubitemid 40459031)
6. BonariL.,PintoN.,AhnE.,EinarsonA.,SteinerM.&KorenG.(2004). Perinatalriskofuntreateddepressionduringpregnancy.CanadianJournalofPsychiatry49, 726-735.(Pubitemid40100521)
7. Bonari L., Koren G., Einarson T.R., Jasper J.D., Taddio A. & Einarson A. (2005). Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and deter-minants of decision making. Archives of Women's Mental Health 8, 214-220. (Pubitemid 41618841)
8. Boucher N., Bairam A. & Beaulac-Baillargeon L. (2008). A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. Journal of Clinical Psychopharmacology 28, 334-339.
9. Campagne D.M. (2007). Fact: antidepressant and anxiolytics are not safe during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology 135, 145-148.
10. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J. & Jones K.L. (1996). Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine 335, 1010-1015. (Pubitemid 26338730)
11. Chun-Fai-Chan B., Koren G., Fayez I., Kaira S.,Voyer-Lavigne S., Boshier A., Shakir S. & Einarson A. (2005). Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. American Journal of Obstetrics & Gynecology 192, 932-936. (Pubitemid 40311292)
12. CiprianiA.,NosèM.&BarbuiC.(2007).Whatisariskratio? EpidemiologiaePsichiatriaSociale16,20-21.(Pubitemid46548574)
13. Cohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., Suri R., Burt V.K., Hendrick V., Reminik A.M., Loughead A., Vitonis A.S. & Stowe Z.N. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. Journal of the American Medical Association 295, 499-507. (Pubitemid 43200344)
14. De Las Cuevas C., Alvarez de La Rosa M., Troyano J.M. & Sanz E.J. (2007). Are psychotropics drugs used in pregnancy? Pharmacoepidemiology and Drug Safety 16, 1018-1023.
15. Dennis C.L., Ross L.E. & Grigoriadis S. (2007). Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database of Systematic Reviews 3, CD006309.
16. Diav-Citrin O., Shechtman S. & Weinbaum D. (2002). Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Teratology 65, 298.
17. DjulusJ.,KorenG.,EinarsonT.R.,WiltonL.,ShakirS.,Diav-CitrinO.,KennedyD., Voyer-LavigneS.,DeSantisM.&EinarsonA.(2006).Exposure- mirtazapineduringpregnancy.Aprospectiveandcomparativestudyofbirthoutcomes. JournalofClinicalPsychiatry67,1280-1284.(Pubitemid44439703)
18. EdwardsG.J.,InmanW.H.,WiltonL.&PearceG.L.(1994).Prescription- eventmonitoringof10401patientstreatedwithfluvoxamine. BritishJournalofPsychiatry164,387-395.(Pubitemid24095299)
19. Einarson A. (2005). The safety of psychotropic drugs during pregnancy: a review. Medscape General Medicine 7, 3. Retrieved April 2, 2008, from http://medscape.com.
20. Einarson A., Fatoye B., Sarkar M., Voyer-Lavigne S., Brochu J., Chambers C., Mastroiacovo P., Addis A., Matsui D., Schuler L., Einarson T.R. & Koren G. (2001a). Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. American Journal of Psychiatry 158, 1728-1730. (Pubitemid 32923672)
21. Einarson A., Selby P. & Koren G. (2001b). Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. Journal of Psychiatry and Neuroscience 26, 44-48.
22. Einarson A., Bonari L., Voyer-Lavigne S., Addis A., Matsui D., Johnoson Y. & Koren G. (2003). A multicentre prospective controlled study to determine the safety of trazodone and nefazodone used during pregnancy. Candian Journal of Psychiatry 48, 106-110.
23. Einarson A., Pistelli A., DeSantis M., Malm H., Paulus W.D., Panchaud A., Kennedy D., Einarson T.R. & Koren G. (2008). Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. American Journal of Psychiatry 165, 749-752.
24. Ericson A., Kallen B. & Wiholom B.E. (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 55, 503-508. (Pubitemid 29446550)
25. Garcia-Enguidanos A., Vaero J., Luna S. & Dominguez-Rojas V. (2002). Risk factors in miscarriage: a review. European Journal of Obstetrics & Gynecology and Reproductive Biology 102, 111-119.
26. Gavin N.I., Gaynes B.N., Lohr K.N., Meltzer-Brody S., Gartlehner G. & Swinson T. (2005). Perinatal depression a systematic review of prevalence and incidence. Obstetrics & Gynecology 106, 1071-1083.
27. Gentile S. (2005). SSRIs in pregnancy and lactation. Focus on neurodevelopmental outcome. CNS Drug Safety 28, 137-152.
28. Gentile S. (2007). Serotonin reuptake inhibitor-induced perinatal complications. Pediatric Drugs 9, 97-106.
29. Gentile S. & Bellantuono C. (2009). SSRI-Exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. Journal of Clinical Psychiatry 70, 414-422.
30. Goldstein D.J., Corbin L.A. & Sundell K.L. (1997). Effects of firsttrimester fluoxetine exposure on the newborn. Obstetrics & Gynecology 89, 713-718.
31. Hemels M.E.H., Einarson A., Koren G., Lanctôt K.L. & Einarson T.R. (2005). Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Annals of Pharmacotherapy 39, 803-809.
32. Kulin A.N., Pastuszak A., Sage S.R., Schick-Boschetto B., Spivey G., Feldkamp M., Ormod K., Matsui D., Stein-Schechman A.K., Cook L., Brochu J., Rieder M. & Koren G. (1998). Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Journal of the American Medical Association 279, 609-611.
33. Louik C., Lin A.E., Werler M.M., Hernández-Dìaz S. & Mitchell A.A. (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine 356, 2675-2683.
34. Maconochie L., Doyle P., Prior. & Simmons R. (2007). Risk factors for first trimester miscarriage - results from a UK-population-based case-control-study. British Journal of Obstetrics and Gynaecolgy 114, 170-186.
35. Malm H., Klaukka T. & Neuvonen P.J. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics & Gynecology 106, 1289-1296.
36. Mc Elhatton P.R., Garbis H.M., Elefant E., Vial T., Bellemin B., Mastroiacovo P., Arnon J., Rodriguez-Pinilla E., Schaefer C., Pexieder T., Merlob P. & Dal Verme S. (1996). Outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressant. A collaborative study of European Network of Teratology Information and Service (ENTIS). Reproductive Toxicology 10, 285-294.
37. National Institute for Health and Clinical Excellence, (2007). Antenatal and Postnatal Mental Health. Clinical Management and Service Guidance. NICE Clinical Guideline 45. Nationai Institute for Health and Clinical Excellence: London.
38. Nonacs R. & Cohen L.S. (2003). Assessment and treatment of depression during pregnancy: an update. Psychiatric Clinics of North America 26, 547-562.
39. Nulman I., Rovet J., Stewart D.E., Wolpin J., Gardner H.A., Theis J.G.W., Kulin N. & Koren G. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine 336, 258-262.
40. Osborn J.F., Cattaruzza M.S. & Spinelli A. (2002). Risk of spontaneous abortion in Italy, 1978-1995, and the effect of maternal age, gravidity, marital status, and education. American Journal of Epidemiology 151, 98-105.
41. Pastuszak A., Schick-Boschetto B., Zuber C., Feldkamp M., Pinelli M., Silin S., Donnenfeld A., McCormack M., Leen-Mitchell M. & Woodland C. (1993). Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). Journal of the American Medical Association 269, 2246-2249.
42. Rahimi R., Nikfar S. & Abdollahi M. (2006). Pregnancy outcome following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reproductive Toxicology 22, 571-575.
43. Ramos E., St-André M., Ray E., Oraichi D. & Bérard A. (2008). Duration of antidepressant use during pregnancy and risk of major congenital malformations. British Journal of Psychiatry 192, 344-350.
44. Simon G.E., Cunningham M.L. & Davis R.L. (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 159, 2055-2061.
45. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A. & Koren G. (2005). Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and foetal outcome. American Journal of Obstetrics & Gynecology 193, 2004-2009. (Pubitemid 41737626)
46. Spinelli M.G. & Endicott J. (2003). Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. American Journal of Psychiatry 160, 555-562.
47. Suri R., Altshuler L., Hendrick V., Rasgon N., Lee E. & Mintz J. (2004). The impact of depression and fluoxetine treatment on obstetrical outcome. Archives of Women's Mental Health 7, 193-200.
48. Suri R., Altshuler L., Hellemann G., Burt V.K., Aquino A. & Mintz J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth, American Journal of Psychiatry 164, 1206-1213.
49. Yaris F., Kadioglu M., Kesim M., Ulku C., Yaris E., Kalyoncu N.I. & Unsal M. (2004). Newer antidepressants in pregnancy: prospective outcome of a case series. Reproductive Toxicology 19, 235-238.
50. Yaris F., Ulku C., Kesim M., Kadioglu M., Unsal M., Fevzi Dikici M., Kalyoncu N.I. & Yaris E. (2005). Psychotropic drugs in pregnancy: a case-control study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 333-338.
51. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun. O., Nimrod C & Walker M. (2006). Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American Journal of Obstetrics & Gynecology 194, 961-966.
52. Wisner K.L, Zarin D.A., Holmboe E.S., Appelbaum P.S., Gelenberg A.J., Leonard H.L. & Frank E. (2000). Risk-benefit decision making for treatment of depression during pregnancy. American Journal of Psychiatry 157, 1933-1940.